Compugen forms collaborations with pharmaceutical, biotechnology and diagnostic companies to develop and commercialize the wide range of discoveries in its portfolio as well as to jointly discover novel candidates for therapeutics. We are focused on in-silico predictive discovery of biologics – peptides, proteins, and antibody targets. Our discoveries are based on more than a decade of interdisciplinary research, with more than 50 publications in peer-reviewed journals, leading to 12 discovery platforms announced so far. We model biological data and systematically predict and select novel product candidates. In the last few years we showed positive results in at least one disease model for more than five peptide and protein drug candidates, all of them discovered in-house, validating by that our internal capabilities. Our general approach is to collaborate early under milestone and revenue sharing agreements. We are interested to collaborate based on a “discovery on demand” model in which a discovery platform is harnessed to discover novel candidates based on guidelines provided by the partner (e.g. indications, targets, pathways). We are also interested to collaborate around candidates we have already discovered, usually after initial proof of concept in an animal disease model. We expect to work together with the partner throughout the discovery stage as well as the pre-clinical and early clinical stages, providing an exclusive license to the partner for further clinical development and commercialization.
For joint discovery, we expect the partner to define a certain need that we will address. Examples from collaborations to date include: finding novel proteins in a given protein family of interest; finding novel peptides that will block a given protein target; and finding novel membrane targets for therapeutic mAbs that would be relevant for a specific indication. Compugen’s discovery programs include identification of novel GPCR peptides ligands (and GPCR ligand library), Disease Associated Conformation peptide blockers, Protein-Protein Interaction Blockers, peptides for intracellular drug delivery, targets for monoclonal antibodies, new indications for existing drugs, pathway kinetic simulation, drug response genomic markers, drug-induced toxicity biomarkers, immunoassay and nucleic acids diagnostics, and more.
A sample list of our collaborations to date includes: